Growth sustains
Growth stalls
Skyrizi and Rinvoq offset the Humira cliff to keep funding the AbbVie dividend
Humira legacy
revenue eroding
Skyrizi
replacement growth
Rinvoq
replacement growth
Immunology growth
replacement offset
Revenue engine
immunology mix
Free cash flow
funds the payout
Dividend payout
annual payout
Dividend raises
53-yr streak
payout vs FCF
durability holds
FCF covers payout
durability weakens
payout ratio rises